Zentalis Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Zentalis Pharmaceuticals generated cash of -$207,822,000, which is less than the previous year. Cash used in financing activities reached the amount of $237,303,000 last year. Net change in cash is therefore -$14,977,000.
Cash Flow
| 2018 | -24.25M | -227K | 9.47M |
|---|---|---|---|
| 2019 | -39.14M | -352K | 81.83M |
| 2020 | -86.82M | -284.83M | 360.43M |
| 2021 | -154.09M | -18.11M | 178.52M |
| 2022 | -163.75M | -114.18M | 261.04M |
| 2023 | -207.82M | -44.45M | 237.30M |
ZNTL Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 45.69M | 62.58M | 56.27M | 67.48M | 25.15M | 40.16M |
Operating activities | ||||||
Net income | -292.19M | -237.11M | -166.09M | -118.54M | -46.37M | -23.43M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 1.38M | 1.42M | 544K | 160K | 111K | 51K |
Stock-based compensation expense | 54.82M | 46.84M | 35.73M | 23.14M | 617K | 0 |
| Deferred income tax benefit | 54.82M | 46.84M | 35.73M | 23.14M | 617K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 413K | -277K | 777K | -254K |
Inventories | 0 | 0 | 881K | -5.51M | -1.50M | -1.86M |
Accounts payable | 10.91M | 15.52M | 13.91M | 14.30M | 7.12M | 977K |
Cash generated by operating activities | -207.82M | -163.75M | -154.09M | -86.82M | -39.14M | -24.25M |
Investing activities | ||||||
Purchases Of Investments | -549.18M | -533.16M | -363.50M | -400.98M | 0 | 0 |
Investments In Property Plant And Equipment | -583K | -2.54M | -6.10M | -758K | -352K | -227K |
Acquisitions Net | 0 | 111.63K | -14.32M | 18.42M | 0 | 0 |
Cash generated by investing activities | -44.45M | -114.18M | -18.11M | -284.83M | -352K | -227K |
Financing activities | ||||||
Common Stock Issued | 237.30M | 261.04M | 179.66M | 327.78M | 81.83M | 16K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -1.14K | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 237.30M | 261.04M | 178.52M | 360.43M | 81.83M | 9.47M |
Net Change In Cash | -14.97M | -16.88M | 6.31M | -11.21M | 42.33M | -15.00M |
Cash at end of period | 30.71M | 45.69M | 62.58M | 56.27M | 67.48M | 25.15M |
| Data source | Data source | Data source | Data source |